Clinical Trial Update: A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the safety and effectiveness of CNTO 888 administered intravenously in participants with idiopathic pulmonary fibrosis. The trial has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• CNTO 888

Snippet

Sponsor: Centocor, Inc. | Conditions: Pulmonary Fibrosis | Phase 2 | Status: COMPLETED